Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy
Conditions: Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm; Symptomatic COVID-19 Infection Laboratory-Confirmed Interventions: Other: Best Practice; Drug: Leflunomide; Drug: Placebo Administration Sponsors: City of Hope Medical Center; National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials